Teladoc Health (NYSE:TDOC) Issues FY 2025 Earnings Guidance

Teladoc Health (NYSE:TDOC) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of -1.100–0.500 for the period, compared to the consensus estimate of -1.030. The company issued revenue guidance of $2.5 billion-$2.6 billion, compared to the consensus revenue estimate of $2.5 billion. Teladoc Health also updated its Q1 2025 guidance to -0.400–0.150 EPS.

Teladoc Health Trading Down 11.4 %

Shares of NYSE:TDOC traded down $1.26 during mid-day trading on Thursday, hitting $9.73. The company had a trading volume of 11,469,450 shares, compared to its average volume of 8,110,355. The firm has a fifty day moving average price of $10.61 and a 200 day moving average price of $9.53. The company has a market capitalization of $1.68 billion, a PE ratio of -1.69 and a beta of 1.04. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.73 and a quick ratio of 1.69. Teladoc Health has a one year low of $6.76 and a one year high of $15.95.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings results on Wednesday, February 26th. The health services provider reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.07). The business had revenue of $640.49 million for the quarter, compared to the consensus estimate of $639.44 million. Teladoc Health had a negative net margin of 37.91% and a negative return on equity of 10.06%. As a group, research analysts forecast that Teladoc Health will post -1.16 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on TDOC shares. Bank of America boosted their price target on shares of Teladoc Health from $11.50 to $13.50 and gave the company a “neutral” rating in a research note on Wednesday, February 12th. Barclays upped their target price on shares of Teladoc Health from $10.00 to $12.00 and gave the stock an “overweight” rating in a research note on Thursday, October 31st. Piper Sandler reduced their target price on shares of Teladoc Health from $13.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday. Needham & Company LLC reiterated a “hold” rating on shares of Teladoc Health in a research note on Thursday. Finally, Oppenheimer cut their price target on shares of Teladoc Health from $14.00 to $12.00 and set an “outperform” rating on the stock in a report on Friday, January 24th. Eleven equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $11.44.

Insider Buying and Selling at Teladoc Health

In other news, insider Carlos Nueno sold 2,389 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $11.93, for a total transaction of $28,500.77. Following the sale, the insider now directly owns 2,890 shares in the company, valued at $34,477.70. This represents a 45.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 0.95% of the company’s stock.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.